Novartis to pay $245 mln to end antitrust cases over Exforge drug generics - Reuters
/cloudfront-us-east-2.images.arcpublishing.com/reuters/UQPIK3T2DVOX7EIO4QZCM5HIAA.jpg)
Novartis AG (NOVN.S) said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versi…
NEW YORK, Dec 28 (Reuters) - Novartis AG (NOVN.S) said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United State… [+1530 chars]
Read More
Other Stories in Business
- Gulf War veteran executed for 1998 quadruple murder despite claims of mental illness
- Guardant Health (GH) Reports Strong Q1 2025 Revenue Growth
- Connecting Asia's startup ecosystem
- Connecting Asia's startup ecosystem
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- Business First Bancshares, Inc. (BFST) Q1 2025 Earnings Call Transcript
